G D'Haens

Summary

Affiliation: Imelda Hospital
Country: Belgium

Publications

  1. ncbi request reprint Advances in medical therapy for Crohn's disease
    Geert D'Haens
    Department of Gastroenterology, University of Leuven, Herestraat 49, 3000 Leuven, Belgium
    Curr Gastroenterol Rep 4:506-12. 2002
  2. ncbi request reprint Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study
    G D'Haens
    Department of Gastroenterology, Imelda General Hospital, Imelda GI Clinical Research Center, Imeldalaan, Bonheiden, Belgium
    Aliment Pharmacol Ther 24:1087-97. 2006
  3. doi request reprint Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial
    Geert R D'Haens
    Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gastroenterology 135:1123-9. 2008
  4. doi request reprint Top-down therapy for IBD: rationale and requisite evidence
    Geert R D'Haens
    Imelda GI Clinical Research Center, Imeldalaan 9, 2820 Bonheiden, Belgium
    Nat Rev Gastroenterol Hepatol 7:86-92. 2010
  5. doi request reprint Anti-TNF-alpha treatment strategies: results and clinical perspectives
    G D'Haens
    Imelda GI Clinical Research Centre, Imelda General Hospital, Imeldalaan 9, 2820 Bonheiden, Belgium
    Gastroenterol Clin Biol 33:S209-16. 2009
  6. ncbi request reprint Top-down therapy for Crohn's disease: rationale and evidence
    G R D'Haens
    Imelda GI Clinical Research Centre, Bonheiden, Belgium
    Acta Clin Belg 64:540-6. 2009
  7. doi request reprint Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease
    Geert R D'Haens
    Irnelda GI Clinical Research Center, Bonheiden, Belgium
    Inflamm Bowel Dis 15:1599-604. 2009
  8. doi request reprint Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
    Geert D'Haens
    Imelda Gastrointestinal Clinical Research Centre, Bonheiden, Belgium
    Lancet 371:660-7. 2008
  9. ncbi request reprint A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
    Geert D'Haens
    University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 132:763-86. 2007
  10. ncbi request reprint Advances in biologic therapy for ulcerative colitis and Crohn's disease
    Geert D'Haens
    Imelda GI Clinical Research Center, Imelda General Hospital, Department of Gastroenterology, Bonheiden, Belgium
    Curr Gastroenterol Rep 8:506-12. 2006

Detail Information

Publications23

  1. ncbi request reprint Advances in medical therapy for Crohn's disease
    Geert D'Haens
    Department of Gastroenterology, University of Leuven, Herestraat 49, 3000 Leuven, Belgium
    Curr Gastroenterol Rep 4:506-12. 2002
    ..In fistulizing disease, infliximab is becoming the treatment of choice, although fistula tracks do not disappear permanently and many patients still need surgical intervention...
  2. ncbi request reprint Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study
    G D'Haens
    Department of Gastroenterology, Imelda General Hospital, Imelda GI Clinical Research Center, Imeldalaan, Bonheiden, Belgium
    Aliment Pharmacol Ther 24:1087-97. 2006
    ..SPD476 (MMX mesalazine), is a novel, once daily, high-strength mesalazine formulation (1.2 g/tablet) that utilizes Multi Matrix System (MMX) technology to delay and extend delivery of the active drug throughout the colon...
  3. doi request reprint Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial
    Geert R D'Haens
    Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gastroenterology 135:1123-9. 2008
    ..Goal: We sought to examine whether metronidazole for 3 months together with azathioprine (AZA) for 12 months is superior to metronidazole alone to reduce recurrence of postoperative CD in "high-risk" patients...
  4. doi request reprint Top-down therapy for IBD: rationale and requisite evidence
    Geert R D'Haens
    Imelda GI Clinical Research Center, Imeldalaan 9, 2820 Bonheiden, Belgium
    Nat Rev Gastroenterol Hepatol 7:86-92. 2010
    ..Identification of suitable patients, however, remains a challenge, as genetic, phenotypic and environmental factors have not yet been identified that can be used for routine assessment and selection is mainly based on clinical criteria...
  5. doi request reprint Anti-TNF-alpha treatment strategies: results and clinical perspectives
    G D'Haens
    Imelda GI Clinical Research Centre, Imelda General Hospital, Imeldalaan 9, 2820 Bonheiden, Belgium
    Gastroenterol Clin Biol 33:S209-16. 2009
    ..There is a clear tendency to use anti TNF therapy earlier in the course of inflammatory bowel disease, but predictive markers to select patients who really need these therapies are urgently needed...
  6. ncbi request reprint Top-down therapy for Crohn's disease: rationale and evidence
    G R D'Haens
    Imelda GI Clinical Research Centre, Bonheiden, Belgium
    Acta Clin Belg 64:540-6. 2009
    ..The key to successful management of Crohn's disease appears to lie in careful timing and selection of the appropriate interventions...
  7. doi request reprint Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease
    Geert R D'Haens
    Irnelda GI Clinical Research Center, Bonheiden, Belgium
    Inflamm Bowel Dis 15:1599-604. 2009
    ..The proposed instruments will need further validation and standardization to demonstrate that they are reliable in stable disease and responsive to change, and to determine the cutoff points for response and remission...
  8. doi request reprint Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
    Geert D'Haens
    Imelda Gastrointestinal Clinical Research Centre, Bonheiden, Belgium
    Lancet 371:660-7. 2008
    ..We aimed to compare the effectiveness of early use of combined immunosuppression with conventional management in patients with active Crohn's disease who had not previously received glucocorticoids, antimetabolites, or infliximab...
  9. ncbi request reprint A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
    Geert D'Haens
    University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 132:763-86. 2007
  10. ncbi request reprint Advances in biologic therapy for ulcerative colitis and Crohn's disease
    Geert D'Haens
    Imelda GI Clinical Research Center, Imelda General Hospital, Department of Gastroenterology, Bonheiden, Belgium
    Curr Gastroenterol Rep 8:506-12. 2006
    ..Only the chimeric monoclonal anti-TNF antibody infliximab is currently available worldwide. The potency of this agent in moderate-to-severe UC and CD has been one of the most important advances in the care of IBD in the past decade...
  11. ncbi request reprint Advances in medical therapy for Crohn's disease
    Geert D'Haens
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, Leuven, Belgium
    Curr Gastroenterol Rep 6:496-505. 2004
    ..Extracorporeal apheresis and even stem cell transplantation were found to be effective in isolated patients, but these therapies warrant further prospective and controlled investigation...
  12. doi request reprint Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    Filip Baert
    Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
    Gastroenterology 138:463-8; quiz e10-1. 2010
    ..Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease...
  13. ncbi request reprint Management of ulcerative colitis and Crohn's disease
    F Baert
    Department of Gastroenterology, at the University Hospital Gasthuisberg, Leuven, Belgium
    Acta Clin Belg 59:304-14. 2004
    ..A large array of new rationally designed biologicals, with a better safety profile and equally selectively acting is underway, and is likely to change our current practise even more dramatically in the next decade...
  14. ncbi request reprint The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study
    L Marchal
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Aliment Pharmacol Ther 19:749-54. 2004
    ..By temporarily suppressing the immune response, the anti-tumour necrosis factor agent, infliximab, may increase the risk of peri-operative complications...
  15. ncbi request reprint Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
    G D'Haens
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 116:1029-34. 1999
    ..Tumor necrosis factor (TNF) is a pivotal cytokine in intestinal inflammation. Controlled trials using a chimeric anti-TNF antibody (infliximab) have shown its efficacy in refractory Crohn's disease...
  16. ncbi request reprint Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis
    G D'Haens
    Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 120:1323-9. 2001
    ..We investigated the effects of intravenous (IV) cyclosporine as single IV therapy (without glucocorticosteroids) for severe UC and compared these with the response to glucocorticosteroids...
  17. ncbi request reprint Quality assurance and recommendations for quality assessment of screening colonoscopy in Belgium
    E Macken
    Department of Gastroenterology, UZ Antwerp, Belgium
    Acta Gastroenterol Belg 72:17-25. 2009
    ..Our goal of this update is to provide practical guidelines for endoscopists performing screening colonoscopy. We hope to provide a broad consensus and an increasing adherence to these recommendations...
  18. ncbi request reprint Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis
    Sofie Joossens
    Department of Gastroenterology, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium
    Clin Chem 50:1422-5. 2004
  19. ncbi request reprint A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis
    Scott Plevy
    Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA
    Gastroenterology 133:1414-22. 2007
    ....
  20. ncbi request reprint Biological therapy in the management of recent-onset Crohn's disease: why, when and how?
    Mark Lowenberg
    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
    Drugs 66:1431-9. 2006
    ..Further research will have to determine whether corticosteroid therapy augments the mechanism of loss of tolerance in Crohn's disease, which could complicate future clinical management...
  21. ncbi request reprint Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn
    Mark Lowenberg
    Laboratory of Experimental Internal Medicine, Academic Medical Center, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Blood 106:1703-10. 2005
    ..These results identify the inhibition of Lck and Fyn kinases as rapid targets of GCs, mediated via a GC receptor-dependent pathway...
  22. ncbi request reprint Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease
    Mark Lowenberg
    Laboratory of Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    J Immunol 175:2293-300. 2005
    ..Our observations indicate that c-Raf inhibitors are prime candidates for the treatment of CD...
  23. ncbi request reprint A role for STAT5 in steroid-resistant UC?
    Mark Lowenberg
    Inflamm Bowel Dis 12:665. 2006